Aegerion Pharmaceuticals, Inc. 4
4 · Aegerion Pharmaceuticals, Inc. · Filed Nov 30, 2016
Insider Transaction Report
Form 4
Chan Barbara Y
See Remarks
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2016-11-29−26,000→ 0 totalExercise: $1.58Exp: 2026-07-01→ Common Stock (26,000 underlying)
Footnotes (2)
- [F1]25% of the shares of common stock underlying this stock option award were to vest on July 1, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through July 1, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.
- [F2]Pursuant to the Agreement and Plan of Merger, dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, the option to purchase common stock of the Issuer was exchanged for an option to purchase 26,665 common shares of Novelion Therapeutics Inc. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."